$1.03
2.58% today
Nasdaq, Sep 16, 08:17 pm CET
ISIN
US81750R1023
Symbol
MCRB
Sector
Industry

Seres Therapeutics Inc Stock price

$1.00
+0.17 20.68% 1M
+0.22 28.70% 6M
-0.40 28.63% YTD
-1.96 66.24% 1Y
-4.89 83.04% 3Y
-2.79 73.64% 5Y
-50.40 98.06% 10Y
Nasdaq, Closing price Fri, Sep 13 2024
+0.04 4.08%
ISIN
US81750R1023
Symbol
MCRB
Sector
Industry

Key metrics

Market capitalization $152.26m
Enterprise Value $293.66m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 793.68
P/S ratio (TTM) P/S ratio 411.51
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth -99.71%
Revenue (TTM) Revenue $370.00k
EBIT (operating result TTM) EBIT $-163.05m
Free Cash Flow (TTM) Free Cash Flow $-184.64m
Cash position $71.23m
EPS (TTM) EPS $-1.18
P/E forward negative
P/S forward 5.89
EV/Sales forward 11.37
Short interest 14.60%
Show more

Is Seres Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,912 stocks worldwide.

Seres Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Seres Therapeutics Inc forecast:

3x Buy
50%
2x Hold
33%
1x Sell
17%

Analyst Opinions

6 Analysts have issued a Seres Therapeutics Inc forecast:

Buy
50%
Hold
33%
Sell
17%

Financial data from Seres Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '23
+/-
%
126 126
1,672% 1,672%
100%
- Direct Costs 15 15
28% 28%
12%
111 111
2,451% 2,451%
88%
- Selling and Administrative Expenses 58 58
3% 3%
46%
- Research and Development Expense 146 146
16% 16%
115%
-92 -92
61% 61%
-73%
- Depreciation and Amortization 15 15
28% 28%
12%
EBIT (Operating Income) EBIT -107 -107
56% 56%
-85%
Net Profit -114 -114
55% 55%
-90%

In millions USD.

Don't miss a Thing! We will send you all news about Seres Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Seres Therapeutics Inc Stock News

Neutral
GlobeNewsWire
3 days ago
CAMBRIDGE, Mass., Sept. 13, 2024 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that the Company, will participate in the Cantor Global Healthcare Conference and Eric Shaff, President and Chief Executive Officer, will represent Seres in a presentation on September 18, 2024 at 3:05 p.m. ET.
Neutral
GlobeNewsWire
4 days ago
SER-155 administration was associated with a significant reduction in both bacterial bloodstream infections (BSIs) and systemic antibiotic exposure, as well as lower incidence of febrile neutropenia, as compared to placebo through day 100 post HSCT
Neutral
Seeking Alpha
about one month ago
Seres Therapeutics, Inc. (NASDAQ:MCRB ) Q2 2024 Earnings Conference Call August 13, 2024 8:30 AM ET Company Participants Carlo Tanzi - IR Eric Shaff - CEO Lisa von Moltke - Chief Medical Officer Marella Thorell - CFO Matthew Henn - EVP, Chief Scientific Officer Teresa Young - EVP, Chief Commercial & Strategy Officer, Conference Call Participants Tessa Romero - JPMorgan Chase & Co. Edward Tentho...
More Seres Therapeutics Inc News

Company Profile

Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. Its product pipeline includes SER-109, SER-287, SER-301, and SER-401. The company was founded by Geoffrey von Maltzahn, David A. Berry, and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.

Head office United States
CEO Eric Shaff
Employees 233
Founded 2010
Website www.serestherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today